
Aethlon Medical AEMD
$ 4.82
14.37%
Quarterly report 2025-Q3
added 11-12-2025
Aethlon Medical Deferred Revenue 2011-2025 | AEMD
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Aethlon Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 345 K | 115 K | 100 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 345 K | 100 K | 186 K |
Quarterly Deferred Revenue Aethlon Medical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 574 K | 574 K | 459 K | 345 K | 230 K | 115 K | 115 K | 115 K | - | 507 K | 307 K | 100 K | 100 K | 100 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 574 K | 100 K | 280 K |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
24.3 M | - | - | $ 17.2 B | ||
|
AdaptHealth Corp.
AHCO
|
34.9 M | $ 9.47 | -2.87 % | $ 1.27 B | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
Butterfly Network
BFLY
|
16.1 M | $ 2.75 | -1.79 % | $ 582 M | ||
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
Delcath Systems
DCTH
|
170 K | $ 9.32 | -2.71 % | $ 266 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
Establishment Labs Holdings
ESTA
|
1.75 M | $ 68.04 | 0.37 % | $ 1.92 B | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 14.36 | 0.97 % | $ 94.1 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 47.91 | 0.1 % | $ 7.14 K | ||
|
Globus Medical
GMED
|
22.1 M | $ 89.76 | -0.09 % | $ 12.2 B | ||
|
Boston Scientific Corporation
BSX
|
306 M | $ 99.38 | -1.65 % | $ 146 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Helius Medical Technologies
HSDT
|
148 K | $ 4.11 | 9.77 % | $ 2.5 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
10.5 M | $ 13.33 | 2.05 % | $ 1.03 B | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
Apyx Medical Corporation
APYX
|
500 K | $ 4.09 | 1.74 % | $ 142 M | ||
|
Accuray Incorporated
ARAY
|
82.3 M | $ 1.03 | 1.47 % | $ 106 M | ||
|
Inogen
INGN
|
5.48 M | $ 6.77 | -2.66 % | $ 160 M | ||
|
IRIDEX Corporation
IRIX
|
2.4 M | $ 0.91 | -2.0 % | $ 14.7 M | ||
|
IRadimed Corporation
IRMD
|
2.26 M | $ 92.81 | 0.54 % | $ 1.18 B | ||
|
Integer Holdings Corporation
ITGR
|
4.44 M | $ 70.25 | -2.08 % | $ 2.36 B | ||
|
Align Technology
ALGN
|
1.33 B | $ 150.68 | 2.7 % | $ 11.3 B | ||
|
LivaNova PLC
LIVN
|
10.8 M | $ 63.67 | 0.89 % | $ 3.45 B | ||
|
Cognyte Software Ltd.
CGNT
|
127 M | $ 8.41 | 3.19 % | $ 604 M | ||
|
LENSAR
LNSR
|
1.68 M | $ 10.32 | 0.68 % | $ 119 M | ||
|
AxoGen
AXGN
|
14 K | $ 27.83 | -2.47 % | $ 1.23 B | ||
|
Pulmonx Corporation
LUNG
|
135 K | $ 1.79 | 1.7 % | $ 70 M | ||
|
Alphatec Holdings
ATEC
|
10.5 M | $ 21.42 | -2.46 % | $ 3.06 B | ||
|
ClearPoint Neuro
CLPT
|
2.12 M | $ 13.46 | -2.07 % | $ 364 M | ||
|
Myomo
MYO
|
2.51 K | $ 0.89 | -0.46 % | $ 6.28 M | ||
|
Nemaura Medical
NMRD
|
124 K | - | -17.8 % | $ 2.74 M |